Efficacy of regorafenib combined with programmed death receptor 1 inhibitor as second-line treatment for advanced hepatocellular carcinoma and analysis of prognostic influencing factors
ZHANG Yu
ZHENG Peng
HUANG Tao
Abstract：Objective To observe the efficacy of regorafenib combined with programmed death receptor 1(PD-1)inhibitor as second-line treatment for advanced hepatocellular carcinoma(HCC)and to analyze the prognostic in-fluencing factors.Methods Fifty-two patients with advanced HCC were treated with regorafenib combined with PD-1 inhibitor.The treatment effect and adverse reactions were observed.Univariate analysis and multivariate Cox re-gression analysis were used to analyze the prognostic factors of 52 patients with advanced HCC.Results After treatment with regorafenib combined with PD-1 inhibitor,52 patients with advanced HCC achieved complete remis-sion(CR)in 1 case(1.92%),partial remission(PR)in 15 cases(28.85%),stable disease(SD)in 21 cases(40.38%),and progressive disease(PD)in 15 cases(28.85%);the objective response rate(ORR)was 30.77%(16/52),and the disease control rate(DCR)was 71.15%(37/52);the median progression-free survival(mPFS)was 8.4 months,and the median overall survival(mOS)was 15.8 months.The most common adverse re-actions were hand-foot syndrome(25 cases),followed by diarrhea(18 cases)and hypertension(18 cases).Subse-quent reactions in descending order of frequency included fatigue(13 cases),pain(12 cases),nausea(11 cases),anorexia(11 cases),elevated transaminases(11 cases),hyperbilirubinemia(8 cases),hypothyroidism(8 cases),rash(7 cases),vomiting(7 cases),fever(6 cases),foot numbness(4 cases),hemoptysis(4 cases),gastroin-testinal bleeding(3 cases),and gingival bleeding(2 cases).Univariate analysis showed that patients without extra-hepatic metastasis in the past,who had received local treatment in the past,with Child-Pugh grade A,and at BCLC-B stage,had significantly prolonged mPFS,and the differences were statistically significant(all P<0.05);multivari-ate analysis showed that Child-Pugh grade B and BCLC-C stage were independent risk factors for mPFS in patients with advanced HCC treated with regorafenib combined with PD-1 inhibitor.Conclusions Regorafenib combined with PD-1 inhibitor as second-line treatment for advanced HCC patients has significant efficacy and controllable ad-verse reactions.Child-Pugh grade B and BCLC-C stage are independent risk factors affecting the poor prognosis of HCC patients.
Keywords：regorafenibprogrammed death receptor 1 inhibitorhepatocellular carcinomaChild-Pugh gradeBCLC stage
Publication Date：2025-04-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 73-77 )